Andrew Scanga - Concepedia

Author

Andrew Scanga

Indiana University – Purdue University Indianapolis ORCID

Also Known As

A. Scanga, Andrew E Scanga, Andrew E. Scanga, Andrew Scanga, Brenner, David A.

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Vanderbilt University Medical Center The University of Texas MD Anderson Cancer Center Texas Liver Institute

About

Andrew Scanga is an author at Indiana University – Purdue University Indianapolis specializing in hepatology, medicine, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	6	1.2K
2	Hepatology	5	6	1.2K
3	Gastroenterology	2	2	210
4	Health Sciences	1	2	876
5	Pathology	1	2	876

Andrew Scanga

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Gastroenterology	2019	326
The Role of Focal Adhesion Kinase-Phosphatidylinositol 3-Kinase-Akt Signaling in Hepatic Stellate Cell Proliferation and Type I Collagen Expression Shimon Reif, Alon Lang, Jeffery N. Lindquist, Journal of Biological Chemistry	2003	292
DNase I-hypersensitive sites enhance α1(I) collagen gene expression in hepatic stellate cells Yutaka Yata, Andrew Scanga, Andrea Gillan, Hepatology	2003	201
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension Guadalupe García–Tsao, Jaime Bosch, Zeid Kayali, Journal of Hepatology Severe Portal HypertensionHepatologyLiver PhysiologyGastroenterologyPlacebo-controlled Trial	2019	152
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study Samer Gawrieh, Lara Dakhoul, Ethan Miller, Alimentary Pharmacology & Therapeutics	2019	130
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis Catherine Frenette, Zeid Kayali, Edward Mena, Journal of Hepatology HepatologyLiver PhysiologyGastroenterologyNew DecompensationHepatotoxicity	2020	58
COMPASS: A Pilot Trial of an Early Palliative Care Intervention for Patients With End-Stage Liver Disease Myrick C. Shinall, Mohana Karlekar, Sara Martin, Journal of Pain and Symptom Management Palliative CarePilot TrialHepatologyLiver DiseaseLiver Cancer	2019	57
Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States Meaghan Phipps, Alexandra E. Livanos, Averill Guo, The American Journal of Gastroenterology	2020	41
Portal Vein Stenosis: A Rare Yet Clinically Important Cause of Delayed-onset Ascites after Adult Deceased Donor Liver Transplantation: Two Case Reports Nina Schneider, Andrew Scanga, LeAnn S. Stokes, Transplantation Proceedings Transplantation SurgeryPortal Vein StenosisTransplantationHepatologyDelayed-onset Ascites	2011	30

Page 1